Longitudinal gut microbiome dynamics in rectal cancer: associations with neoadjuvant therapy and tumor regression
9 affiliations
- 1Department of Surgery, University Hospital Greifswald, 17475 Greifswald, Germany
- 2Department of Pediatrics, Klinikum Stuttgart, Olgahospital, 70174 Stuttgart, Germany
- 3Department of Internal Medicine I, University Hospital Erlangen, 91054 Erlangen, Germany
- 4Department of Surgery, University Hospital Erlangen, 91054 Erlangen, Germany
- 5Institute of Pathology, University Hospital Greifswald, 17475 Greifswald, Germany
- 6Department of Nephrology, University Hospital Erlangen, 91054 Erlangen, Germany
- 7Department of Internal Medicine B, University Hospital Münster, 48149 Münster, Germany
- 8Department of Internal Medicine II, Infectious Diseases, Goethe University Frankfurt, 60590 Frankfurt, Germany
- 9German Cancer Consortium (DKTK), partner site Frankfurt am Main, a partnership between DKFZ and University Hospital Frankfurt, Frankfurt, Germany
Abstract
Background: The gut microbiome has emerged as a key modulator of colorectal cancer biology, influencing tumor progression and therapeutic response. However, most existing studies analyze colorectal cancer as a single entity despite biological and therapeutic differences between colon and rectal cancer. Consequently, longitudinal data linking microbiome dynamics to treatment response, particularly in rectal cancer, remain limited.
Methods: In this prospective cohort study, 31 patients with rectal cancer were included, of whom 17 received neoadjuvant therapy and 14 underwent primary surgery. A total of 110 stool and tissue samples were collected at defined time points before, during, and after treatment. Microbial composition and diversity were analyzed using 16S rRNA gene sequencing. Alpha and beta diversity metrics, differential abundance analyses, and longitudinal comparisons were performed to assess treatment-related microbiome alterations.
Results: Distinct microbial communities were observed between stool and tissue samples, with stool samples enriched in Bacteroidetes and tissue samples dominated by Firmicutes, Actinobacteria, and Verrucomicrobia. Neoadjuvant therapy was associated with a marked reduction in microbial diversity with no recovery before surgery, and community composition shifted significantly over the treatment course (patient-constrained PERMANOVA, p = 0.0016), with Clostridium XIVa becoming the dominant genus before surgery. Longitudinal analyses further revealed exploratory differences between patients with complete and incomplete tumor regression. Between diagnosis and surgery, patients achieving complete tumor regression (Dworak TRG 4) showed an increase in the propionate-producing genus Phascolarctobacterium, the only genus significant after correction for multiple testing, together with an exploratory rise in the butyrate-producing genus Roseburia. Higher Bacteroides in patients with incomplete regression was a descriptive observation that was not statistically significant (p = 0.35, q = 0.71). No genus-level differences between response groups were detected at baseline after correction for multiple testing; however, the small sample size limits the ability to exclude baseline differences.
Conclusions: Rectal cancer treatment induces distinct and time-dependent alterations in the gut microbiome. Complete tumor regression was associated with an increase in short-chain fatty acid–producing taxa, led by the propionate producer Phascolarctobacterium, whereas higher Bacteroides in incomplete responders was a non-significant, exploratory observation. Given the growing role of organ-preserving strategies such as watch-and-wait, in which reliable identification of complete response is critical, these exploratory patterns warrant validation in larger cohorts.
Supplementary information: The online version contains supplementary material available at https://doi.org/10.1186/s12866-026-05859-y.
Related
- Longitudinal gut microbiome changes during the chemoradiotherapy component of total neoadjuvant therapy for rectal cancer
- Longitudinal associations of the gut microbiome with arterial stiffness in US adults: findings from the Baltimore Longitudinal Study of Aging
- Fecal microbiome dynamics across reproductive stages in primiparous Świniarka sheep: a longitudinal study
- Longitudinal multi-omics analysis identify multi-kingdom microbiome-host interaction dynamics and diagnostic biomarkers of postoperative infection after kidney transplantation
- Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy.
BibTeX
@article{jentzsch2026longitudinal,
title = {{Longitudinal gut microbiome dynamics in rectal cancer: associations with neoadjuvant therapy and tumor regression}},
author = {Jael Jentzsch and Stefan Wirtz and Maximilian Brunner and Silvia Ribback and Barbara Kneis and Klaus Weber and Axel Denz and Robert Grützmann and Robert Schierwagen and Olaf Tyc and Jonel Trebicka and Stephan Kersting and Melanie Langheinrich},
journal = {BMC Microbiology},
year = {2026},
month = nov,
doi = {10.1186/s12866-026-05859-y},
url = {https://doi.org/10.1186/s12866-026-05859-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Longitudinal gut microbiome dynamics in rectal cancer: associations with neoadjuvant therapy and tumor regression
AU - Jael Jentzsch
AU - Stefan Wirtz
AU - Maximilian Brunner
AU - Silvia Ribback
AU - Barbara Kneis
AU - Klaus Weber
AU - Axel Denz
AU - Robert Grützmann
AU - Robert Schierwagen
AU - Olaf Tyc
AU - Jonel Trebicka
AU - Stephan Kersting
AU - Melanie Langheinrich
PY - 2026
DA - 2026/11/04
JO - BMC Microbiology
DO - 10.1186/s12866-026-05859-y
UR - https://doi.org/10.1186/s12866-026-05859-y
AB - Background: The gut microbiome has emerged as a key modulator of colorectal cancer biology, influencing tumor progression and therapeutic response. However, most existing studies analyze colorectal cancer as a single entity despite biological and therapeutic differences between colon and rectal cancer. Consequently, longitudinal data linking microbiome dynamics to treatment response, particularly in rectal cancer, remain limited. Methods: In this prospective cohort study, 31 patients with rectal cancer were included, of whom 17 received neoadjuvant therapy and 14 underwent primary surgery. A total of 110 stool and tissue samples were collected at defined time points before, during, and after treatment. Microbial composition and diversity were analyzed using 16S rRNA gene sequencing. Alpha and beta diversity metrics, differential abundance analyses, and longitudinal comparisons were performed to assess treatment-related microbiome alterations. Results: Distinct microbial communities were observed between stool and tissue samples, with stool samples enriched in Bacteroidetes and tissue samples dominated by Firmicutes, Actinobacteria, and Verrucomicrobia. Neoadjuvant therapy was associated with a marked reduction in microbial diversity with no recovery before surgery, and community composition shifted significantly over the treatment course (patient-constrained PERMANOVA, p = 0.0016), with Clostridium XIVa becoming the dominant genus before surgery. Longitudinal analyses further revealed exploratory differences between patients with complete and incomplete tumor regression. Between diagnosis and surgery, patients achieving complete tumor regression (Dworak TRG 4) showed an increase in the propionate-producing genus Phascolarctobacterium, the only genus significant after correction for multiple testing, together with an exploratory rise in the butyrate-producing genus Roseburia. Higher Bacteroides in patients with incomplete regression was a descriptive observation that was not statistically significant (p = 0.35, q = 0.71). No genus-level differences between response groups were detected at baseline after correction for multiple testing; however, the small sample size limits the ability to exclude baseline differences. Conclusions: Rectal cancer treatment induces distinct and time-dependent alterations in the gut microbiome. Complete tumor regression was associated with an increase in short-chain fatty acid–producing taxa, led by the propionate producer Phascolarctobacterium, whereas higher Bacteroides in incomplete responders was a non-significant, exploratory observation. Given the growing role of organ-preserving strategies such as watch-and-wait, in which reliable identification of complete response is critical, these exploratory patterns warrant validation in larger cohorts. Supplementary information: The online version contains supplementary material available at https://doi.org/10.1186/s12866-026-05859-y.
SN - 1471-2180
ER -